Symbiotec Pharmalab IPO Subscription Day 1: Issue Subscribed 0.14x, Retail at 0.20x

Mumbai, August 24: The Symbiotec Pharmalab IPO opened for subscription on Monday, August 24, 2026, and saw a relatively slow start during the first few hours of bidding. As of 10:54 AM on Day 1, the ₹1,757 crore public issue was subscribed 0.14 times, according to the subscription data shown.

The IPO has a price band of ₹938 to ₹988 per share, with investors required to bid for a minimum of 15 shares. At the upper end of the price band, a retail investor needs ₹14,820 to apply for one lot.

Retail Investors Lead the Early Bidding

The retail category was subscribed 0.20 times by 10:54 AM. Against the 62,13,562 shares reserved for retail investors, bids were received for 12,54,000 shares.

The NII segment was subscribed 0.17 times, with bids for 4,58,385 shares against 26,62,955 shares on offer.

Within the NII category, the smaller HNI segment, or sNII, was subscribed 0.29 times, while the bNII portion stood at 0.11 times.

The QIB (Ex Anchor) category had not picked up yet, showing a subscription level of 0.00 times, with no bids recorded against the 35,50,608 shares offered to the category at the time of reporting.

The employee portion was subscribed 0.28 times, with bids received for 9,360 shares against 33,408 shares reserved for employees.

Overall, the issue had received bids for 17,21,745 shares, compared with 1,24,60,533 shares on offer, resulting in the overall subscription of 0.14 times. The number of applications stood at 63,880.

Symbiotec Pharmalab IPO details

Symbiotec Pharmalab is looking to raise around ₹1,757 crore through the IPO. The issue comprises a fresh issue of 15,21,261 shares, aggregating to ₹150 crore, and an offer for sale of 1,62,65,181 shares, amounting to ₹1,607 crore at the upper price band.

The IPO opened on August 24 and will close on August 27, 2026. The tentative allotment date is August 28, followed by the expected credit of shares on August 31. The company is scheduled to list on September 1, 2026, on both the NSE and BSE.

The company has fixed the face value at ₹2 per share, while the IPO price band is ₹938-₹988 per share. The employee category is also eligible for a ₹90 per share discount.

What does the Day 1 Response Indicate?

The opening numbers show that investors have been cautious so far. Retail and NII participation has started, but neither category has come close to full subscription, while QIB bidding was yet to begin in the reported data.

That said, this is only the first-day morning snapshot. IPO subscription activity can change sharply during the final two days, particularly once institutional participation picks up. Investors will therefore be watching the Day 2 and Day 3 numbers closely before drawing a firm conclusion on the overall demand for the issue.

About Symbiotec Pharmalab

Symbiotec Pharmalab Ltd., incorporated in 2002, operates in the pharmaceutical and biotechnology space. The company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products, serving both domestic and international markets.

The company says it has more than three decades of industry experience and has developed its manufacturing operations from a lab-scale steroid hormone API business into an industrial-scale, backward-integrated platform.

Conclusion

The Symbiotec Pharmalab IPO has opened on a cautious note, with the issue subscribed 0.14 times by 10:54 AM on the first day. Retail investors have shown comparatively stronger early participation at 0.20 times, while the NII category stood at 0.17 times.

For now, the IPO remains far from full subscription, and the bigger test will come over the next two sessions as HNI and institutional bidding gathers pace.

Source:

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active